GENETHON

• Hansa Biopharma announced positive Phase 2 results for imlifidase in Guillain-Barré Syndrome (GBS), showing rapid functional improvement in patients. • The company completed enrollment in the pivotal Phase 3 GOOD-IDES-02 trial of imlifidase for anti-glomerular basement membrane (anti-GBM) disease. • A Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome has been initiated in collaboration with Genethon. • Hansa Biopharma anticipates submitting a Biologics License Application (BLA) to the FDA for imlifidase in kidney transplantation in late 2025.

• Phase 2 data indicates imlifidase, combined with IVIg, significantly improves motor function and accelerates recovery in Guillain-Barré Syndrome (GBS) patients. • An indirect comparison showed GBS patients treated with imlifidase and IVIg returned to independent walking six weeks sooner than those treated with IVIg alone. • Hansa Biopharma and Genethon initiated a Phase 2 trial using imlifidase as a pretreatment to broaden access to gene therapy for Crigler-Najjar syndrome. • Hansa Biopharma completed enrollment in a Phase 3 trial of imlifidase for anti-GBM disease, with data expected in 2025.

Genethon's GNT0004, a gene therapy for Duchenne muscular dystrophy (DMD), demonstrates positive initial results in a Phase 1/2/3 clinical trial, showing stable or improved motor function in treated patients.

Genethon's GNT0004 gene therapy demonstrated good tolerability in boys with Duchenne muscular dystrophy when combined with transient immunological prophylactic treatment.